Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pimicotinib + itraconazole
- Development stage
- Unknown
- Lead developer
- Abbisko Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pimicotinib (ABSK021/ABSK201) is a potent, highly selective small-molecule inhibitor of the colony-stimulating factor 1 receptor (CSF-1R). It is developed by Abbisko Therapeutics for the treatment of tenosynovial giant cell tumor (TGCT), a condition characterized by the overexpression of CSF-1. The combination of pimicotinib with itraconazole is specifically utilized in Phase 1 clinical trials to evaluate pharmacokinetic drug-drug interactions. Itraconazole, a strong inhibitor of the CYP3A4 enzyme, is administered alongside pimicotinib to determine the extent to which CYP3A4-mediated metabolism affects the systemic exposure and safety profile of pimicotinib. This study is crucial for understanding the metabolic clearance of pimicotinib and for providing dosing recommendations when co-administered with other CYP3A4 modulators.
- Brand names
- Sporanox
- Other names
- ABSK201 + itraconazoleABSK021 + itraconazole
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on pimicotinib + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pimicotinib + itraconazole.